Acorda Therapeutics Company Profile (NASDAQ:ACOR)

About Acorda Therapeutics

Acorda Therapeutics logoAcorda Therapeutics, Inc. is a biopharmaceutical company. The Company is engaged in the identification, development and commercialization of therapies that restore function and recovers the lives of people with neurological disorders. Its commercial products include Ampyra, Fampyra, Zanaflex Capsules and a generic version of the capsules, Zanaflex tablets and Qutenza. Its research and development programs include CVT-301, Dalfampridine, Plumiaz, Neuregulin Program, Remyelinating Antibodies Program, CVT-427 and Chondroitinase Program. Its Ampyra is an oral drug for the treatment to improve walking in patients with multiple sclerosis. Zanaflex Capsules and tablets are used as short-acting drugs for the management of spasticity. Qutenza is a dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia. Its pipeline of neurological therapies addresses a range of disorders, including Parkinson's disease, chronic post-stroke walking deficits and migraine.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: ACOR
  • CUSIP: 00484M10
Key Metrics:
  • Previous Close: $20.64
  • 50 Day Moving Average: $24.68
  • 200 Day Moving Average: $26.07
  • 52-Week Range: $20.51 - $43.63
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 30.71
  • P/E Growth: 1.62
  • Market Cap: $964.20M
  • Outstanding Shares: 46,090,000
  • Beta: 1.46
  • Net Margins: -1.08%
  • Return on Equity: 1.00%
  • Return on Assets: 0.53%
  • Debt-to-Equity Ratio: 0.43%
  • Current Ratio: 1.93%
  • Quick Ratio: 1.53%
Additional Links:
Companies Related to Acorda Therapeutics:

Analyst Ratings

Consensus Ratings for Acorda Therapeutics (NASDAQ:ACOR) (?)
Ratings Breakdown: 1 Sell Rating, 3 Hold Ratings, 3 Buy Ratings
Consensus Rating:Hold (Score: 2.29)
Consensus Price Target: $41.57 (99.10% upside)

Analysts' Ratings History for Acorda Therapeutics (NASDAQ:ACOR)
DateFirmActionRatingPrice TargetDetails
8/25/2016Stifel NicolausReiterated RatingBuyView Rating Details
8/25/2016JPMorgan Chase & Co.Reiterated RatingNeutralView Rating Details
8/25/2016Cowen and CompanyReiterated RatingOutperform$65.00View Rating Details
6/1/2016AegisBoost Price TargetBuy$40.00 -> $52.00View Rating Details
5/22/2016Leerink SwannReiterated RatingHold$31.00 -> $29.00View Rating Details
5/20/2016Evercore ISIReiterated RatingHold$32.00View Rating Details
3/30/2016Goldman Sachs Group Inc.Initiated CoverageSell$23.00View Rating Details
8/31/2015Raymond James Financial Inc.Initiated CoverageMarket PerformView Rating Details
7/31/2015Canaccord GenuityReiterated RatingHold$32.00View Rating Details
6/22/2015MLV & Co.Set Price TargetBuy$58.00View Rating Details
6/9/2015GuggenheimInitiated CoverageNeutralView Rating Details
4/22/2015Piper Jaffray Cos.Initiated CoverageNeutralView Rating Details
2/13/2015Citigroup Inc.Reiterated RatingHold$46.00 -> $42.00View Rating Details
2/11/2015Royal Bank Of CanadaSet Price TargetBuy$45.00View Rating Details
10/31/2014FBR & CoReiterated RatingOutperform$57.00 -> $59.00View Rating Details
10/30/2014MKM PartnersBoost Price TargetNeutral$31.50 -> $33.00View Rating Details
(Data available from 9/30/2014 forward)


Earnings History for Acorda Therapeutics (NASDAQ:ACOR)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/28/2016Q216$0.18$0.07$128.33 million$127.45 millionViewListenView Earnings Details
4/28/2016Q116$0.08$0.07$115.36 million$115.90 millionViewListenView Earnings Details
2/11/2016Q415$0.22$0.28$128.24 million$130.90 millionViewListenView Earnings Details
10/22/2015Q315$0.15$0.31$115.52 million$148.20 millionViewListenView Earnings Details
7/30/2015Q215$0.17$0.31$110.84 million$113.70 millionViewListenView Earnings Details
4/30/2015Q115$0.03($0.02)$100.20 million$99.85 millionViewN/AView Earnings Details
2/12/2015Q414$0.14$0.46$110.80 million$117.90 millionViewN/AView Earnings Details
10/30/2014Q314$0.05$0.28$94.70 million$106.00 millionViewN/AView Earnings Details
7/31/2014Q214$0.15$0.42$91.40 million$97.13 millionViewN/AView Earnings Details
5/6/2014Q114$0.09$0.21$81.30 million$80.52 millionViewN/AView Earnings Details
2/19/2014Q413$0.18$0.32$89.96 million$92.59 millionViewN/AView Earnings Details
10/31/2013Q313$0.13$0.36$90.01 million$84.92 millionViewListenView Earnings Details
8/1/2013Q2 2013$0.09$0.25$82.57 million$87.05 millionViewListenView Earnings Details
5/2/2013Q1 2013$0.20$0.09$80.77 million$71.90 millionViewListenView Earnings Details
2/13/2013Q4 2012$0.15$0.24$78.90 million$81.47 millionViewListenView Earnings Details
10/31/2012Q312$0.10$0.38$75.20 million$77.44 millionViewN/AView Earnings Details
7/31/2012$0.27$0.27ViewN/AView Earnings Details
5/3/2012$0.27$0.36ViewN/AView Earnings Details
2/16/2012$0.24$0.40ViewN/AView Earnings Details
11/4/2011$0.82$0.47ViewN/AView Earnings Details
8/1/2011$0.10$0.01ViewN/AView Earnings Details
5/5/2011$0.17($0.02)ViewN/AView Earnings Details
2/17/2011$0.17$0.09ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Acorda Therapeutics (NASDAQ:ACOR)
Current Year EPS Consensus Estimate: $0.47 EPS
Next Year EPS Consensus Estimate: $0.68 EPS


Dividend History for Acorda Therapeutics (NASDAQ:ACOR)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Acorda Therapeutics (NASDAQ:ACOR)
Insider Ownership Percentage: 8.00%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/23/2016Jane WasmanInsiderSell500$27.32$13,660.00View SEC Filing  
6/22/2016David LawrenceInsiderSell500$25.09$12,545.00View SEC Filing  
6/8/2016Steven M RauscherDirectorSell1,086$27.83$30,223.38View SEC Filing  
5/13/2016Andrew A HindmanInsiderSell4,860$26.11$126,894.60View SEC Filing  
4/19/2016Lorin RandallDirectorSell1,488$28.68$42,675.84View SEC Filing  
1/4/2016Ian F. SmithDirectorSell13,231$41.85$553,717.35View SEC Filing  
12/23/2015Jane WasmaninsiderSell10,751$43.10$463,368.10View SEC Filing  
12/22/2015Lauren M. SabellainsiderSell7,113$42.04$299,030.52View SEC Filing  
12/21/2015Jane WasmanInsiderSell817$42.00$34,314.00View SEC Filing  
12/18/2015David LawrenceinsiderSell39,026$40.63$1,585,626.38View SEC Filing  
12/17/2015Lauren M. SabellainsiderSell14,229$40.00$569,160.00View SEC Filing  
12/1/2015Enrique J CarrazanaInsiderSell7,218$38.08$274,861.44View SEC Filing  
12/1/2015Ron CohenCEOSell11,850$38.08$451,248.00View SEC Filing  
10/19/2015Andrew BlightinsiderSell32,500$30.87$1,003,275.00View SEC Filing  
10/7/2015Michael W. RogersCFOSell5,700$30.24$172,368.00View SEC Filing  
10/5/2015Jane WasmaninsiderSell3,750$31.75$119,062.50View SEC Filing  
10/5/2015Ron CohenCEOSell135,000$28.03$3,784,050.00View SEC Filing  
9/21/2015Andrew BlightinsiderSell13,085$31.30$409,560.50View SEC Filing  
5/15/2015Andrew A HindmanInsiderSell4,779$29.82$142,509.78View SEC Filing  
1/12/2015Enrique J CarrazanaInsiderSell97,993$42.21$4,136,284.53View SEC Filing  
12/18/2014David LawrenceInsiderSell27,109$40.11$1,087,341.99View SEC Filing  
12/18/2014John P KelleyDirectorSell10,000$40.00$400,000.00View SEC Filing  
12/1/2014David LawrenceInsiderSell8,898$35.60$316,768.80View SEC Filing  
12/1/2014Lauren M SabellaVPSell3,242$35.58$115,350.36View SEC Filing  
12/1/2014Michael W RogersCFOSell230$35.58$8,183.40View SEC Filing  
12/1/2014Ron CohenCEOSell34,394$35.59$1,224,082.46View SEC Filing  
10/7/2014Michael W RogersCFOSell5,700$33.10$188,670.00View SEC Filing  
10/3/2014Jane WasmanInsiderSell3,750$34.13$127,987.50View SEC Filing  
9/24/2014Jane WasmanInsiderSell14,923$36.00$537,228.00View SEC Filing  
8/27/2014Jane WasmanInsiderSell14,923$33.00$492,459.00View SEC Filing  
12/5/2013Lauren SabellaVPSell8,797$31.81$279,832.57View SEC Filing  
12/2/2013Enrique CarrazanaInsiderSell1,640$33.56$55,038.40View SEC Filing  
10/15/2013Enrique J CarrazanaInsiderSell3,333$32.38$107,922.54View SEC Filing  
10/3/2013Jane WasmanInsiderSell3,750$35.74$134,025.00View SEC Filing  
8/20/2013Ron CohenCEOSell149,000$34.10$5,080,900.00View SEC Filing  
8/2/2013John KelleyDirectorSell15,000$38.00$570,000.00View SEC Filing  
7/19/2013Andrew BlightInsiderSell19,296$37.82$729,774.72View SEC Filing  
6/10/2013Ron CohenCEOSell11,000$34.15$375,650.00View SEC Filing  
5/8/2013Sandra Phd PanemDirectorSell10,000$33.80$338,000.00View SEC Filing  
12/4/2012Lauren M SabellaVPSell4,364$24.58$107,267.12View SEC Filing  
12/3/2012Andrew BlightInsiderSell7,200$24.20$174,240.00View SEC Filing  
12/3/2012David LawrenceCFOSell9,313$24.21$225,467.73View SEC Filing  
12/3/2012Ron CohenCEOSell16,407$24.22$397,377.54View SEC Filing  
11/13/2012Sandra Phd PanemDirectorSell22,569$24.12$544,364.28View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Acorda Therapeutics (NASDAQ:ACOR)
DateHeadline logoAcorda Therapeutics, Inc. Gains Title To All Shares In Biotie Therapies Corp. And The Shares Will Delist From Nasdaq Helsinki (NASDAQ:ACOR) - September 30 at 3:28 PM
News IconAcorda Therapeutics, Inc. (NASDAQ:ACOR) Updated Broker Price Targets - The De Soto Edge (NASDAQ:ACOR) - September 30 at 8:03 AM logoACORDA GAINS TITLE TO BIOTIE SHARES AND THE SHARES WILL DELIST (NASDAQ:ACOR) - September 30 at 8:02 AM logoAcorda Therapeutics: New 52-Week Low Set Today (ACOR) (NASDAQ:ACOR) - September 29 at 3:15 PM
News IconLatest Analyst Reports On Acorda Therapeutics, Inc. - NewsDen (NASDAQ:ACOR) - September 28 at 8:03 AM logoThe Arbitral Tribunal Has Confirmed Acorda Therapeutics, Inc.'s Redemption Right Regarding the Shares in Biotie Therapies Corp. And Public Trading in The Shares Has Been Terminated (NASDAQ:ACOR) - September 28 at 8:03 AM
News IconTraders Alert - General Electric Company, (NYSE:GE), Acorda Therapeutics, (NASDAQ:ACOR) - Financial Breaking News (NASDAQ:ACOR) - September 27 at 3:17 PM
News IconEye-Catching Stocks: Juniper Networks, Inc. (NYSE:JNPR), Acorda Therapeutics Inc (NASDAQ:ACOR) - NYSE Journal (press release) (NASDAQ:ACOR) - September 27 at 3:17 PM logoAcorda Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : ACOR-US : September 27, 2016 (NASDAQ:ACOR) - September 27 at 3:17 PM logoMonday Market Wrap: Stocks Fall Nearly 1% To Start Week - Benzinga (NASDAQ:ACOR) - September 27 at 7:22 AM logoMid-Day Market Update: Crude Oil Up 3.3%; Chemtura Shares Surge Following Acquisition News - Benzinga (NASDAQ:ACOR) - September 26 at 3:16 PM logoARBITRAL TRIBUNAL CONFIRMED ACORDA'S REDEMPTION RIGHT REGARDING BIOTIE SHARES AND BIOTIE ... - GlobeNewswire (press release) (NASDAQ:ACOR) - September 26 at 8:31 AM
News IconAnalysts Take the Wheel on Acorda Therapeutics, Inc. (NASDAQ:ACOR) Shares and Where They Might Be Headed - Frisco Fastball (NASDAQ:ACOR) - September 21 at 10:58 AM
News IconDiscover the Asia Pacific rna-based therapeutics market 2016: industry demand, segment, statistics and research to 2021 (NASDAQ:ACOR) - September 19 at 8:04 AM logoAcorda Launches “The Many Faces of OFF” Facebook Page to ... - Business Wire (press release) (NASDAQ:ACOR) - September 15 at 3:16 PM
News IconAcorda Launches The Many Faces of OFF Facebook Page to Support Parkinsons Community (NASDAQ:ACOR) - September 15 at 12:08 PM logoAcorda Launches “The Many Faces of OFF” Facebook Page to Support Parkinson’s Community (NASDAQ:ACOR) - September 15 at 12:08 PM logoTakeda Says 2nd Circ. Zanaflex Ruling Torpedoes Actos Row (NASDAQ:ACOR) - September 14 at 8:34 PM logoAcorda Therapeutics, Inc. – Value Analysis (NASDAQ:ACOR) : September 14, 2016 (NASDAQ:ACOR) - September 14 at 3:17 PM logoAcorda Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : ACOR-US : September 13, 2016 (NASDAQ:ACOR) - September 13 at 3:17 PM
News IconPlacing Acorda Therapeutics, Inc. (NASDAQ:ACOR) Shares Under the Microscope (NASDAQ:ACOR) - September 9 at 3:16 PM
News IconWhat is the Sell-side Saying About Acorda Therapeutics, Inc. (NASDAQ:ACOR)? - Frisco Fastball (NASDAQ:ACOR) - September 9 at 8:04 AM
News IconPlacing Acorda Therapeutics, Inc. (NASDAQ:ACOR) Shares Under the Microscope - National Daily Press (NASDAQ:ACOR) - September 9 at 8:04 AM
News IconPain Management Market (Abuse Deterrent Era) - US Opioids Market is $8B in Size and of Which Extended Release Formulations Contribute 50% (NASDAQ:ACOR) - September 8 at 3:16 PM logoNoteworthy Thursday Option Activity: IONS, ACOR, MON (NASDAQ:ACOR) - September 8 at 3:16 PM logoETF’s with exposure to Acorda Therapeutics, Inc. : September 6, 2016 (NASDAQ:ACOR) - September 6 at 3:16 PM
News IconStock in Review: Taking a Closer Look at Acorda Therapeutics, Inc. (NASDAQ:ACOR) Shares - Post News (NASDAQ:ACOR) - September 2 at 3:19 PM
News IconShares Slipping Lower Over the Past Month: Acorda Therapeutics, Inc. (NASDAQ:ACOR) - Post News (NASDAQ:ACOR) - September 1 at 3:16 PM logoWhy Does The Smart Money Like Acorda Therapeutics? - Insider Monkey (blog) (NASDAQ:ACOR) - August 31 at 3:17 PM
News IconWhy Does The Smart Money Like Acorda Therapeutics? (NASDAQ:ACOR) - August 31 at 12:54 PM
News IconThe Listing Committee Of Nasdaq Helsinki Has Resolved To Delist The Shares Of Biotie (NASDAQ:ACOR) - August 27 at 8:04 AM logoBiotie: BTT1023 receives Orphan Drug Designation in the United States (NASDAQ:ACOR) - August 26 at 11:23 AM logoNotable Thursday Option Activity: ACOR, PG, SFL (NASDAQ:ACOR) - August 26 at 11:23 AM logoBiotie Therapies : THE LISTING COMMITTEE OF NASDAQ HELSINKI HAS RESOLVED TO DELIST THE SHARES OF BIOTIE THERAPIES CORP. (NASDAQ:ACOR) - August 26 at 11:23 AM logo7:32 am Acorda Therapeutics' Biotie confirms it was granted orphan designation by the FDA for BTT1023 for the treatment of primary sclerosing cholangitis (NASDAQ:ACOR) - August 26 at 11:23 AM logoETF’s with exposure to Acorda Therapeutics, Inc. : August 26, 2016 (NASDAQ:ACOR) - August 26 at 11:23 AM logoAcorda Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : ACOR-US : August 25, 2016 (NASDAQ:ACOR) - August 25 at 3:16 PM logoTHE LISTING COMMITTEE OF NASDAQ HELSINKI HAS RESOLVED TO DELIST THE SHARES OF BIOTIE THERAPIES CORP. (NASDAQ:ACOR) - August 25 at 8:05 AM logoAcorda Therapeutics Can Deliver Sustained Growth - Seeking Alpha (NASDAQ:ACOR) - August 24 at 3:19 PM
News IconHuman Biobanking Ownership Market Analysis and Industry Overview 2016 to 2024 (NASDAQ:ACOR) - August 24 at 11:35 AM logoAcorda CEO: EpiPen increase 'far in excess' of industry s... (NASDAQ:ACOR) - August 23 at 8:36 PM logoWatch List: China Cord Blood Corporation (NYSE:CO), Acorda Therapeutics, Inc. (NASDAQ:ACOR), Interactive ... - KC Register (NASDAQ:ACOR) - August 22 at 8:26 PM logoWill Acorda Therapeutics, Inc. (NASDAQ:ACOR) Hit $60 Price Target? - Investor Newswire (NASDAQ:ACOR) - August 22 at 8:04 AM
News IconStock Tracking Lower for the Quarter: Acorda Therapeutics, Inc. (NASDAQ:ACOR) - Post News (NASDAQ:ACOR) - August 21 at 8:04 AM
News IconCrowd Ratings & Broker Views on Acorda Therapeutics, Inc. (NASDAQ:ACOR)? - Post News (NASDAQ:ACOR) - August 20 at 7:58 AM
News IconShares Moving Lower Over the Past Month Acorda Therapeutics, Inc. (NASDAQ:ACOR) - Post News (NASDAQ:ACOR) - August 18 at 3:17 PM logoBiotie Therapies : CORP. APPLIES FOR DELISTING OF ITS SHARES FROM NASDAQ HELSINKI (NASDAQ:ACOR) - August 18 at 11:41 AM logoBIOTIE THERAPIES CORP. APPLIES FOR DELISTING OF ITS SHARES FROM NASDAQ HELSINKI (NASDAQ:ACOR) - August 18 at 11:41 AM logoACORDA THERAPEUTICS INC Financials (NASDAQ:ACOR) - August 12 at 3:18 PM
News IconUpcoming Earnings Report: Acorda Therapeutics, Inc. (NASDAQ:ACOR) - The Voice Registrar (NASDAQ:ACOR) - August 11 at 3:17 PM


Acorda Therapeutics (NASDAQ:ACOR) Chart for Friday, September, 30, 2016

Last Updated on 9/30/2016 by Staff